LSE - Delayed Quote EUR

Derichebourg SA (0K8W.L)

5.72

-0.03

(-0.51%)

As of July 22 at 8:30:26 AM GMT+1. Market Open.

Costco posts mixed earnings results as consumers seek value amid tariff uncertainty

Costco posts earnings growth as the company navigates an uncertain macro landscape.

Yahoo Finance 14 hours ago

COST
Costco earnings top estimates despite tariffs

Costco (COST) reported third quarter earnings of $4.28 per share compared to the Bloomberg consensus estimate of $4.24. Revenue was $63.21 billion versus an estimated $63.31 billion. Comparable sales, excluding gas and currency impacts, were up 8%. Analysts had anticipated 6.99%. Market Domination Overtime Anchors Julie Hyman and Josh Lipton are joined by Senior Reporter Brooke DiPalma to discuss the results. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 15 hours ago

COST
Dell Earnings, Outlook Were Fantastic. The Stock Is Barely Budging.

Dell Technologies stock was up—barely—after the company gave a strong revenue outlook for the current quarter. For its fiscal first quarter ended in April, the company reported revenue of $23.4 billion, up 5% versus the prior year—above the Wall Street consensus of $23.2 billion, according to FactSet. For the current quarter, Dell forecast a revenue range of $28.5 billion to $29.5 billion, which is above analysts’ expectations of $25.3 billion.

Barrons.com 17 minutes ago

DELL
5 Things to Know Before the Stock Market Opens

News of the day for May 30, 2025

Investopedia 44 minutes ago

COST

DELL
Costco Defies Tariff Shifts With Higher Profit, Lower Prices

(Bloomberg) -- Costco Wholesale Corp. posted better-than-expected earnings in the third quarter, a sign that the nation’s largest club chain is flexing its scale and devoted following to navigate tariffs and economic turbulence. Most Read from BloombergNYC Congestion Toll Brings In $216 Million in First Four MonthsNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNY Wins Order Against US Funding Freeze in Congestion FightWhy Ar

Bloomberg 10 minutes ago

COST

KHC

TGT
Costco Stock: Wholesaler Tops Q3 Earnings, Same-Store Sales Miss

Costco stock trades near a buy zone after its Q3 earnings, revenue beat late Thursday. Same-store sales growth fell short of views.

Investor's Business Daily 56 minutes ago

COST
Costco’s $1.50 hot dog still holds — and so does customer loyalty

The $1.50 Costco hot dog — a still point in a turning world, immune to tariffs, inflation, or even Jay Powell — remains the most reliable deal in America. In a time of relentless volatility, the Costco hot dog stands firm.

Quartz 1 hour ago

COST
Zscaler Stock Jumps. It’s Defying the Cybersecurity Slump This Earnings Season.

The cybersecurity stock rose early Friday, making it an outlier in what's been a tough earnings season for the sector.

Barrons.com 1 hour ago

ZS
UiPath Stock Soars After Earnings, Guidance Hike. Why Wall Street Is More Cautious.

The automation-software company pushed back on fears that cuts in U.S. federal spending may hurt its financial results.

Barrons.com 1 hour ago

PATH
The Nasdaq Bounces Back: These AI Stocks Could Be the Smartest Buys of the Year

After a painful 20% plunge this spring, the Nasdaq Composite has nearly rebounded all the way back. Investors should take a breath now and look at investing in some of the strongest artificial intelligence (AI) companies. The Nasdaq Composite is only at about breakeven for the year, as of this writing, but it's made a powerful comeback in recent weeks.

Motley Fool 1 hour ago

NVDA

COMP

DELL
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.

PR Newswire 1 hour ago

BLRX
Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SMITHS FALLS, Ontario, May 30, 2025--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (Nasdaq: CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") and the fiscal year ended March 31, 2025 ("FY2025") and the filing of the Company’s Annual Report on Form 10-K for FY2025 (the "Form 10-K"), including the audited consolidated financial statements for FY2025 and the unqualified report thereon of the Company’s independent registere

Business Wire 1 hour ago

CGC
Social Buzz: Wallstreetbets Stocks Mixed Premarket Friday; Gap to Decline, Dell Technologies to Advance

The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Friday's

PREMIUM
MT Newswires 1 hour ago

DELL

RDDT
These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More

Nvidia falls after rallying Thursday, Dell rises on better-than-expected financial guidance, and Gap and American Eagle contend with tariff uncertainty.

Barrons.com 1 hour ago

NVDA

MRVL

AEO
Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.

Tariffs are in limbo after court ruling, Powell emphasizes Fed independence, more retail earnings, and more news to start your day.

Barrons.com 1 hour ago

COST

SNPS
Trending tickers: Costco, Dell, Ulta, Adidas and Volkswagen

The latest investor updates on stocks that are trending on Friday

Yahoo Finance UK 1 hour ago

^IXIC

^DJI

ULTA
Regeneron shares slide on mixed trial data for smoker's lung drug

(Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD). The disease has limited treatment options and the drug, itepekimab, was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition.

Reuters 1 hour ago

REGN

SNY
Costco Wholesale Fiscal Third-Quarter Comparable Sales Miss Street Views

Costco Wholesale (COST) reported fiscal third-quarter earnings and revenue above market estimates, b

PREMIUM
MT Newswires 1 hour ago

COST
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug candidate’s late-stage trials.

The Wall Street Journal 1 hour ago

SNY

SNYNF

REGN
The Zacks Analyst Blog Highlights Costco, The Gap, Dell Technologies, Marvell Technology and Ulta Beauty

Costco, Dell, Marvell and Ulta beat estimates, while Gap tumbles 17% despite a Q1 beat.

Zacks 2 hours ago

MRVL

DELL

COST

Performance Overview

Return	0K8W.L	MSCI WORLD (^990100-USD-STRD)
YTD	+10.66%	+4.21%
1-Year	+18.80%	+12.96%
3-Year	-20.06%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Derichebourg SA (0K8W.L)

Related News

Costco posts mixed earnings results as consumers seek value amid tariff uncertainty

Costco earnings top estimates despite tariffs

Dell Earnings, Outlook Were Fantastic. The Stock Is Barely Budging.

5 Things to Know Before the Stock Market Opens

Costco Defies Tariff Shifts With Higher Profit, Lower Prices

Costco Stock: Wholesaler Tops Q3 Earnings, Same-Store Sales Miss

Costco’s $1.50 hot dog still holds — and so does customer loyalty

Zscaler Stock Jumps. It’s Defying the Cybersecurity Slump This Earnings Season.

UiPath Stock Soars After Earnings, Guidance Hike. Why Wall Street Is More Cautious.

The Nasdaq Bounces Back: These AI Stocks Could Be the Smartest Buys of the Year

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Social Buzz: Wallstreetbets Stocks Mixed Premarket Friday; Gap to Decline, Dell Technologies to Advance

These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More

Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.

Trending tickers: Costco, Dell, Ulta, Adidas and Volkswagen

Regeneron shares slide on mixed trial data for smoker's lung drug

Costco Wholesale Fiscal Third-Quarter Comparable Sales Miss Street Views

Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials

The Zacks Analyst Blog Highlights Costco, The Gap, Dell Technologies, Marvell Technology and Ulta Beauty

Performance Overview